PROTECT (2023) — Trial Summary
PROTECT (2023): The PROTECT phase 3 trial evaluated sparsentan, a dual endothelin type A and angiotensin II receptor antagonist, versus irbesartan in adults with IgA nephropathy at risk of progressive kidney function loss.
References
- Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401(10388):1584-1594.